Fig. 9
From: METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis
Knockdown of METTL7B inhibits migration, invasion, and EMT. A Relative expression of METTL7B in LGG and normal brain tissues. B The transfection efficiency of the METTL7B siRNA in HS683 and SHG44 cells, as measured using qRT-PCR. C–D Wound healing assays and Transwell assays indicated the migratory and invasive abilities of glioma cells after transfection. E Western blots showing levels of the Vimentin and N-cadherin proteins in HS683 and SHG44 cells after METTL7B knockdown with an siRNA. Data are represented as the mean values ± SD. * p < 0.05, and ** p < 0.01